Company Description
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases.
The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics.
The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023.
Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jan 12, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Randy D. Milby MBA |
Contact Details
Address: 1200 Route 22 East Bridgewater, New Jersey 08807 United States | |
| Phone | 302-743-2995 |
| Website | tharimmune.com |
Stock Details
| Ticker Symbol | THAR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001861657 |
| ISIN Number | US4327052001 |
| Employer ID | 84-2642541 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Randy D. Milby MBA | President, Chairman and Chief Executive Officer |
| Sireesh Appajosyula Pharm.D. | Chief Operating Officer and Director |
| Thomas P. Hess CPA, MBA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 22, 2024 | ARS | Filing |
| Mar 21, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 21, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 11, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 11, 2024 | 8-K | Current Report |
| Feb 23, 2024 | 10-K | Annual Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 8, 2024 | 8-K | Current Report |
| Dec 12, 2023 | 8-K | Current Report |